The notion “hepatitis” means inflammation of the liver or its cells, often caused by some virus and accompanied in its initial phase to by symptoms similar to flu: fever, loss of appetite, muscle/joint aches, etc. According to the virus type hepatitis is divided into several types: hepatitis A, В C, D and E. Hepatitis can disappear on its own, but in some cases it can lead to serious liver dysfunctions and severe complications such as fibrosis, liver failure or cancer, cryoglobulinemia, an a lot more.
The world hepatitis drugs market has experienced stable growth over the recent years, driven by the constant increase of demand from developed countries, introduction of new products and technological advancement in the medical industry. It is set to continue growing at a CARG of above 12% through 2015. Gilead Sciences, Merck & Co., GlaxoSmithKline, Bristol-Myers Squibb and Hoffmann-La Roche are amid the key hepatitis market players.
The collection of the research reports found in this catalogue provides an extensive insight into the hepatitis market at different geographical scales. Relevant information on the market size, share, segmentation as well as major factors influencing the market is presented in the researches. The reports offer detailed assessment of the competitive landscape and profile top companies. In addition, discussions of future market prospects for the are at hand in the research reports.
Publications found:
152
Sort by:
